Compare STEM & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | RANI |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.9M | 126.8M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | RANI |
|---|---|---|
| Price | $10.37 | $1.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.60 | $8.60 |
| AVG Volume (30 Days) | 169.2K | ★ 830.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.05 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $144,584,000.00 | $1,028,000.00 |
| Revenue This Year | $5.48 | $414.59 |
| Revenue Next Year | $12.51 | $30.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $0.39 |
| 52 Week High | $32.23 | $3.87 |
| Indicator | STEM | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 55.94 |
| Support Level | $0.38 | $1.31 |
| Resistance Level | $21.86 | $1.42 |
| Average True Range (ATR) | 0.79 | 0.09 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 6.62 | 83.67 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.